Immunogenicity and Reactogenicity of Haemophilus influenzae Type b – Meningococcus Group B Outer Membrane Protein Conjugate Vaccine in Children 2–60 Months of Age

References

• Cochi S L, Broome C V, Hightower A W. Immunization of U.S. children with Haemophilus influenzae type polysaccharide vaccine: A cost‐effectiveness model of strategy assessment. JAMA 1985; 253: 521–529
   PubMed Web of Science ®Google Scholar
• Dajani A S, Asmar B I, Thirumoorthi M C. Systemic Haemophilus influenzae disease: an overview. J Pediatr 1979; 94: 355–364
   PubMed Web of Science ®Google Scholar
• Shapiro E D, Murphy T V, Wald E R, Brady C A. The protective efficacy of Haemophilus b polysaccharide vaccine. JAMA 1988; 260: 1419–1422
   PubMed Web of Science ®Google Scholar
• Osterholm M T, Rambeck J H, White K E, Jacobs J L, Pierson L M, Neaton J D, Hedberg C W, MacDonald K L, Granoff D M. Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota. JAMA 1988; 260: 1423–1428
   PubMedGoogle Scholar
• Weinberg G A, Granoff D M. Polysaccharide‐protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease. J Pediatr 1988; 113: 621–631
   PubMed Web of Science ®Google Scholar
• Einhorn M S, Weinberg G A, Anderson E L, Granoff P D, Granoff D M. Immunogenicity in infants of Haemophilus influenzae type b polysaccharide in a conjugate vaccine with Neisseria meningitidis outer‐membrane protein. Lancet 1986; 2: 299–302
   PubMed Web of Science ®Google Scholar
• Lenoir A A, Granoff P D, Granoff D M. Immunogenicity of Haemophilus influenzae type b polysaccharide‐Neisseria meningitidis outer membrane protein conjugate vaccine in 2‐ to 6‐month old infants. Pediatrics 1987; 80: 283–287
   PubMed Web of Science ®Google Scholar
• Marburg S, Jorn D, Tolman R L, Arison B, McCauley J, Knisken P T, Hagopian A, Vella P P. Bimolecular chemistry of macromolecules: Synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein. J Am Chem Soc 1986; 108: 5282–5287
   Web of Science ®Google Scholar
• Kuo J S‐C, Monji N, Schwalbe R S, McCoy D W. A radioactive antigen‐binding assay for the measurement of antibody to Haemophilus influenzae type b capsular polysaccharide. J Immunol Methods 1981; 43: 35–47
   PubMed Web of Science ®Google Scholar
• Ward J I, Greenberg D P, Anderson P W, Burkart J S, Christenson P D, Gordon L K, Käyhty H, Kuo J SC, Vella P. Variable quantitation of Haemophilus influenzae type b anticapsular antibody by radioantigen binding assay. J Clin Microbiol 1988; 26: 72–78
   PubMed Web of Science ®Google Scholar
• Käyhty H, Peltola H, Karanko V, Mäkelä P H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147: 1100
   PubMed Web of Science ®Google Scholar
• Peltola H, Käyhty H, Sivonen A, Mäkelä P H. Haemophilus influenzae type b polysaccharide vaccine in children: a double‐blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60: 730–737
   PubMed Web of Science ®Google Scholar
• Weinberg G A, Einhorn M S, Lenoir A A, Granoff P D, Granoff D M. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide – outer membrane protein conjugate vaccine. J Pediatr 1987; 111: 22–27
   PubMed Web of Science ®Google Scholar
• Granoff D M, Chacko A, Lottenbach K R, Sheetz K E. Immunogenicity of Haemophilus influenzae type b polysaccharide – outer membrane protein conjugate vaccine in patients who acquired Haemophilus disease despite previous vaccination with type b polysaccharide vaccine. J Pediatr 1989; 114: 925–933
   PubMed Web of Science ®Google Scholar
• Shapiro E D, Capobianco L A, Berg A T, Zitt M Q. The immunogenicity of Haemophilus influenzae type b polysaccharide‐Neisseria meningitidis group b outer membrane protein complex vaccine in infants and young children. J Infect Dis 1989; 160: 1064–1067
   PubMed Web of Science ®Google Scholar
• Ahonkai V A, Lukacs L J, Jonas L C, Matthews H, Vella P P, Ellis R W, Staub J M, Dolan K T, Rusk C M, Calandra G B, Gerety R J. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): Clinical evaluation. Pediatrics 1990; 85: 676–681
   PubMed Web of Science ®Google Scholar
• Cochi S L, Broome C V. Vaccine prevention of Haemophilus influenzae type b disease: past, present, and future. Pediatr Infect Dis J 1986; 5: 12–19
   Web of Science ®Google Scholar
• Eskola J, Peltola H, Takala A K, Käyhty H, Hakulinen M, Karanko V, Kela E, Rekola P, Rönnberg P ‐R, Samuelson J S, Gordon L K, Mäkelä P H. Efficacy of Haemophilus influenzae type b polysaccharide‐diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 1987; 317: 717–722
   PubMed Web of Science ®Google Scholar
• Eskola J, Käyhty H, Takala A K, Peltola H, Rönnberg P ‐R, Kela E, Pekkanen E, McVerry P H, Mäkelä P H. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323: 1381–1387
   PubMed Web of Science ®Google Scholar
• Ward J, Brenneman G, Letson G W, Heyward W L, the Alaska H, Influenzae Vaccine Study Group. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med 1990; 323: 1393–1401
   PubMed Web of Science ®Google Scholar
• Claesson B A, Schneerson R, Robbins J B, Johansson J, Lagergård T, Taranger J, Bryla D, Levi L, Cramton T, Trollfors B. Protective levels of serum antibodies stimulated in infants by two injections of Haemophilus influenzae type b polysaccharide‐tetanus toxoid conjugate. J Pediatr 1989; 114: 97–100
   PubMed Web of Science ®Google Scholar